Highest-materiality recent filing
ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.
BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones
BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.
Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.
BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart
Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.
BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track
Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.
BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack
Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.
BioCryst gets FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years
FDA approved ORLADEYO oral pellet formulation for prophylactic therapy in HAE children aged 2 to <12 years.
BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026
HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.
BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria
ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).
BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong
Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.
BioCryst completes sale of European ORLADEYO business; receives $250M upfront
Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.
BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M
Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).
BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor
Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.
BioCryst appoints Babar Ghias as CFO and Head of Corporate Development
Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.
BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M
Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.
BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M
Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.
FDA extends PDUFA goal date for BioCryst's ORLADEYO pediatric NDA to Dec 12, 2025
FDA determined submission of additional final reports and formulation data is a major amendment, extending review by three months.
On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
Max materiality 0.85 · Median 0.75 · Most common event leadership